EARLY-STAGE BREAST CANCER

This Phase 2 trial at Fudan University tests several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see which combinations best eliminate all signs of cancer (pathological complete response) based on each tumor's specific subtype. Ab…

This study tests a new, ultra-short radiation schedule for early-stage breast cancer. Instead of the usual 3 weeks, patients receive 5 radiation sessions over one week, with an extra boost to the tumor site given at the same time. The goal is to see if this approach is safe, redu…

This study tests whether adding an oral probiotic (Biolosion) to standard chemotherapy before surgery can help eliminate more cancer cells in women with early-stage triple-negative breast cancer. About 192 participants will receive either standard treatment alone or standard trea…

This study tests whether a blood test (ctDNA) can identify women with early-stage, hormone-positive breast cancer who can safely avoid chemotherapy. Instead of chemo, they receive a targeted pill (dalpiciclib) plus hormone therapy before surgery. The goal is to reduce side effect…

This study tests whether taking a daily statin (atorvastatin) can prevent heart damage caused by HER2-targeted therapy in women with early-stage breast cancer. About 60 participants will take the statin alongside their cancer treatment. The goal is to reduce treatment delays or e…

This phase II trial is testing whether a targeted drug called trastuzumab deruxtecan (Enhertu), given alone or with anastrozole (Arimidex), can eliminate HER2-low, hormone receptor positive breast cancer before surgery. The study will enroll 88 people with early-stage breast canc…

This Phase 3 trial tests whether a combination of trastuzumab and neratinib works better than the standard trastuzumab and pertuzumab for women with a certain type of breast cancer (HER2-positive, hormone receptor-positive) who still have small amounts of cancer after initial che…

This study tests whether a 24-week exercise program combining brisk walking and strength training can improve survival in women with early-stage breast cancer. Over 2,000 participants will be enrolled within 8 weeks of finishing surgery or chemotherapy. The program starts with in…

This study is testing whether a special test called HER2DX can help doctors choose the best treatment for people with early-stage HER2-positive breast cancer. About 304 participants will be split into two groups: one group gets standard treatment without the test results, and the…

This study is testing a very short course of radiation therapy for women with early-stage breast cancer. Instead of weeks of treatment, participants receive whole breast radiation with a targeted boost over just 5 days. Researchers will track how the breast looks and feels, and h…

This study looks at how different amounts of aerobic exercise (like walking or cycling) over different time periods affect heart and lung fitness in post-menopausal women who had early-stage breast cancer. About 152 women will take part. The goal is to find the best exercise plan…

About half of women stop taking aromatase inhibitors early due to side effects, raising the risk of cancer returning. This study tests whether switching to a different hormone drug or using other symptom-relief methods works better at managing those side effects. Researchers will…

This trial tests whether women with early-stage breast cancer can safely skip a drug called G-CSF during part of their chemotherapy to reduce bone pain. About 242 participants will either receive or skip G-CSF after paclitaxel infusions. The main goal is to see if skipping it low…

This study is testing whether a low dose of the drug azacitidine, given before surgery, can increase immune cells (called tumor-infiltrating lymphocytes) in the tumors of people with high-risk early-stage breast cancer. About 40 participants will receive the drug for a short time…

This study aims to screen 450 early-stage breast cancer survivors for prediabetes, diabetes, high cholesterol, and heart disease risk. Participants complete surveys and provide lab results, and those with risk factors are directed to community resources. The goal is to catch and …

This study is looking at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. These leftover cells, called minimal residual disease (MRD), can sometimes cause the cancer to come back. The study will follow 900 breast cancer …

This pilot study tests whether a personalized approach to heart imaging can safely reduce the number of echocardiograms women with early-stage breast cancer need during HER2-targeted therapy. The goal is to avoid unnecessary tests while still catching any heart side effects early…

This study looks at whether women who finished treatment for early-stage breast cancer can safely reduce their hospital follow-up visits from five years to just two years, while still getting yearly mammograms. About 560 women will take part, with half following the usual schedul…

This study is testing new drug combinations for breast cancer to see which ones work best for different tumor types. It involves up to 5,000 people with early-stage or locally advanced breast cancer. Researchers use MRI scans and tissue samples before surgery to predict treatment…